Why Wall Street Is Worried About Pfizer Despite Its COVID Vaccine Success
Pfizer (NYSE: PFE) just knocked it out of the park with its first-quarter results. Its revenue soared 42% year over year and adjusted earnings per share skyrocketed 48%. The big drugmaker blew away analysts' estimates and significantly raised full-year revenue and earnings guidance.
You might think that Wall Street would have been enthusiastic about such a strong quarterly update. Nope. Pfizer's shares barely moved after the Q1 results were announced. Mizuho Securities analyst Vamil Divan even downgraded Pfizer stock from buy to neutral.
Wall Street certainly appears to be worried about Pfizer despite its huge COVID-19 vaccine success. But why?
Source Fool.com
